Smoking Cessation Leadership Center



University of California San Francisco

The Epidemiology and Treatment of Smoking in People with Mental Illness

Gemma Taylor, PhD, Reader at University of Bath, UK

September 8, 2022

Moderator

Catherine Bonniot

Deputy Director

Smoking Cessation Leadership Center University of California, San Francisco

A National Center of Excellence for Tobacco-Free Recovery

Catherine.Bonniot@ucsf.edu





Disclosures

This UCSF CME activity was planned and developed to uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

All speakers, planning committee members and reviewers have disclosed they have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Catherine Bonniot Saucedo, Anita Browning, Christine Cheng, Brian Clark, Pamela Ling, MPH, MD, Jennifer Matekuare, Ma Krisanta Pamatmat, MPH, Jessica Safier, MA, Gemma Taylor, PhD, and Aria Yow, MA.





Thank you to our funders





September: National Recovery Month



https://www.samhsa.gov/recovery-month



Housekeeping

- All participants will be in listen only mode and the audio will be streaming via your computers.
- Please make sure your computer speakers are on and adjust the volume accordingly.
- If you do not have speakers, please click on the link, 'Listen by Phone' listed on the left side of your screen, for the dial-in number.
- This webinar is being recorded and will be available on SCLC's website, along with a PDF of the slide presentation.
- Use the 'ASK A QUESTION' box to send questions at any time to the presenter.



CME/CEU Statements

Accreditations:

The University of California, San Francisco (UCSF) School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UCSF designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the webinar activity.

Advance Practice Registered Nurses and Registered Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 CreditTM issued by organizations accredited by the ACCME.

Physician Assistants: The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 CreditTM are acceptable for continuing medical education requirements for recertification.

California Pharmacists: The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for *AMA PRA category 1 Credit*TM. If you are a pharmacist in another state, you should check with your state board for approval of this credit.

California Psychologists: The California Board of Psychology recognizes and accepts for continuing education credit courses that are provided by entities approved by the Accreditation Council for Continuing Medical Education (ACCME). *AMA PRA Category 1 Credit*TM is acceptable to meeting the CE requirements for the California Board of Psychology. Providers in other states should check with their state boards for acceptance of CME credit.

California Behavioral Science Professionals: University of California, San Francisco School of Medicine (UCSF) is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for behavioral health providers. UCSF maintains responsibility for this program/course and its content.

Course meets the qualifications for 1.0 hour of continuing education credit for LMFTs, LCSWs, LPCCs, and/or LEPs as required by the California Board of Behavioral Sciences. Provider # 64239.

Respiratory Therapists: This program has been approved for a maximum of 1.0 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care, 9425 N. MacArthur Blvd. Suite 100 Irving TX 75063, Course **#TBD**.

California Addiction Counselors: The UCSF Office of Continuing Medical Education is accredited by the **California Consortium of Addiction Professional and Programs (CCAPP)** to provide continuing education credit for California Addiction Counselors. UCSF designates this live, virtual activity, for a maximum of 1.0 CCAPP credit. Addiction counselors should claim only the credit commensurate with the extent of their participation in the activity. Provider number: 7-20-322-0722.





- Free CME/CEUs will be available for all eligible California providers, who joined this live activity thanks to the support of the California Tobacco Control Program (CTCP)
- For our California residents, SCLC offers regional trainings, online education opportunities, and technical assistance for behavioral health agencies, providers, and the clients they serve throughout the state of California.
- For technical assistance please contact (877) 509-3786 or <u>Jessica.Safier@ucsf.edu</u>.
- Visit <u>CABHWI.ucsf.edu</u> for more information



Today's Presenter

Gemma Taylor, PhD

Reader

University of Bath






THE EPIDEMIOLOGY AND TREATMENT OF SMOKING IN PEOPLE WITH MENTAL ILLNESS

DR GEMMA TAYLOR, PHD







DISCLOSURES AND FUNDING

- This work was partially supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Tobacco Addiction Group.
- I receive funding from a Cancer Research UK Population Researcher Postdoctoral Fellowship award (reference: C56067/A21330) and Cancer Research UK project award (reference: PPRCPJT\100023).
- I report previous funding from Pfizer (GRAND scheme) for an unrelated project.
- I am employed by a scientific consulting company (HEOR) doing work unrelated to this project.

OVERVIEW

- 1) Why is this an important research area?
- 2) A Cochrane systematic review about the association between quitting smoking and mental ill-health.
- 3) The ESCAPE pilot trial intEgrating Smoking Cessation treatment As part of usual Psychological care for dEpression and anxiety.

QR codes throughout – scan with phone camera!




"I was signed off work with depression. I was asked if I smoked and I was encouraged not to try and quit... I was given anti-depressants instead."

- Smoker with depression, male, aged 37



UK SMOKING PREVALENCE IN PEOPLE WITH AND WITHOUT ANXIETY AND DEPRESSION, 2006-2015






Taylor G., et al (2019). Nicotine & Tobacco Research. ntz072, https://doi.org/10.1093/ntr/ntz072.

RATIONALE

People with mental illness:

- Smoke more, are more heavily addicted, and suffer from worse withdrawal
- Less responsive to standard treatments
- Experience a reduction in life expectancy up to 17.5 years
- They are as motivated to quit as the general population



RATIONALE

- A common perception that smoking helps people to manage stress and may be a form of 'self-medication'.
- However, there are biologically plausible reasons why smoking may worsen mental health through neuroadaptations arising from chronic smoking, leading to frequent nicotine withdrawal symptoms (e.g., anxiety, low mood, irritability).
- Therefore, quitting smoking may help to improve rather than worsen mental health.








Cochrane Database of Systematic Reviews

Smoking cessation for improving mental health (Review)

Taylor GMJ, Lindson N, Farley A, Leinberger-Jabari A, Sawyer K, te Water Naudé R, Theodoulou A, King N, Burke C, Aveyard P





Baseline to follow-up (6 weeks>)



METHODS

STUDIES:

- Controlled before-after studies
- RCTs analysed by smoking status at follow-up
- Longitudinal cohort studies
- At least 6 weeks follow-up

PARTICIPANTS:

- Adults who smoked tobacco (using studies own definition)
- No restrictions by population type, or comorbidities





EXPOSURE:

• Quitting smoking (any definition, e.g., self report, bio-validated, preference for most stringent definition)

CONTROL:

• Continued smoking



METHODS - OUTCOMES

CHANGE IN SYMPTOMS OF:

- Anxiety
- Depression
- Stress
- Psychological QOL
- Positive affect
- Mixed anxiety and depression
- Social QOL




METHODS - SEARCHES

- Updated our previous review, inception to April 12 2012 (Taylor, 2014)
- Searched April 13 2012 to January 7 2020: Cochrane tobacco addiction group register, Cochrane central register of controlled trials, Medline, Embase, PsycInfo, clinicaltrials.gov, International Clinical Trials Registry Platform
- Translated non-English studies



Figure 1. Study Flow Diagram 2020





RESULTS

Search results:

- Screened 22,908 titles and abstracts
- Read 971 full-text studies

Included studies:

- Included 102 studies*
- 73 meta-analysed
- 31 narrative synthesis

Included participants:


- >169,500 participants included**
- >42,000 participants meta-analysed**




*2 studies were included in the meta-analysis and narrative review because they reported data suitable for meta-analysis for one outcome, and data only suitable for narrative synthesis for another outcome)** not possible to give exact Ns as some studies did not report total N analysed.

DIFFERENCE IN CHANGE IN DEPRESSION, BETWEEN QUITTERS AND CONTINUING SMOKERS, SMD (95% CI)

Study or Subgroup	SMD	SE	Quitters Total	Smokers Total	Weight	Std. Mean Difference IV, Random, 95% CI	Std. Mean Difference IV, Random, 95% CI	
Covey 2015 (1)	-0.05	0.14	99	126	4.2%	-0.05 [-0.32 , 0.22]	-	-
Bock 2012	-0.4	0.3	16	39	1.7%	-0.40 [-0.99 , 0.19]	_ _	
Martínez-Vispo 2016	-0.48	0.22	57	35	2.6%	-0.48 [-0.91 , -0.05]		
Berlin 2010	-0.3	0.22	27	106	2.6%	-0.30 [-0.73, 0.13]	_ _	
Lubitz 2019	-0.41	0.16	36	143	3.7%	-0.41 [-0.72, -0.10]		
3lalock 2008	-0.58	0.22	9	12	2.6%	-0.58 [-1.01 , -0.15]		
Dawkins 2009	-0.38	0.25	33	31	2.2%	-0.38 [-0.87 , 0.11]		
Garvey 2012	-0.67	0.28	16	90	1.9%	-0.67 [-1.22 , -0.12]		
Franel 2012	-0.08	0.24	32	38	2.4%	-0.08 [-0.55 , 0.39]		
Guimond 2017	0.05	0.19	55		3.1%	0.05 [-0.32 , 0.42]	1	
Moadel 2012	-0.84	0.68	16	108	0.4%	-0.84 [-2.17, 0.49]		
Lopez 2015	-0.5	0.2	28		3.0%	-0.50 [-0.89 , -0.11]		
Solomon 2006	0.01	0.18	45		3.3%	0.01 [-0.34 , 0.36]		
Kahler 2011	-0.28	0.21	31		2.8%	-0.28 [-0.69 , 0.13]		
Dedert 2019	1.53	0.49	6		0.8%	1.53 [0.57 , 2.49]		
Dulger 2019	-0.27	0.29	17		1.8%	-0.27 [-0.84 , 0.30]		
Krebs 2018	-0.13	0.02	87		7.0%	-0.13 [-0.17 , -0.09]		
Lechner 2019	-1.53	0.36	16		1.3%	-1.53 [-2.24 , -0.82]		
Mathew 2013	-0.7	0.35	13		1.4%	-0.70 [-1.39 , -0.01]		
Schnoll 2016	-0.7	0.44	39		0.9%	-0.70 [-1.56 , 0.16]		
Zhou 2016	-0.31	0.08	356		5.8%	-0.31 [-0.47 , -0.15]		
Becoña 2017	-1.62	0.38	52		1.2%	-1.62 [-2.36 , -0.88]		
Bloom 2015	-0.48	0.21	67		2.8%	-0.48 [-0.89 , -0.07]		
Busch 2011	-0.22	0.19	43		3.1%	-0.22 [-0.59 , 0.15]		
Hammett 2019 (2)	-0.06	0.13	111		6.7%	-0.06 [-0.14 , 0.02]	-1	-0.30 (-0.39, -0.21), l ² =69%
Kahler 2002	-0.69	0.04	31		3.0%	-0.69 [-1.08 , -0.30]		
Rocha 2017	-0.83	0.29	47		1.8%	-0.83 [-1.40 , -0.26]		
Rodríguez-Cano 2016	-0.29	0.13	4/ 91		4.5%	-0.29 [-0.54 , -0.04]		
Sankaranarayanan 2016	-0.2	0.29	13		1.8%	-0.20 [-0.77 , 0.37]	-	
Vázquez 1999	-0.12	0.17	56		3.5%	-0.12 [-0.45 , 0.21]		
Lee 2019	-0.12	0.17	11		1.4%	-0.71 [-1.38 , -0.04]		
Martínez-González 2018	-0.58	0.34	53		3.7%	-0.58 [-0.89 , -0.27]		
Munafò 2008	-0.58	0.10	143		5.5%	-0.09 [-0.27 , 0.09]		
Vermeulen 2019 (3)	-0.09	0.09	143		5.2%	-0.09 [-0.27 , 0.09] -0.04 [-0.24 _0.16]	X	
vermemen 2019 (3)	-0.04	0.1	111	008	5.2%	-0.04 [-0.24, 0.16]	<u> </u>	
Fotal (95% CI) Heterogeneity: Tau ² = 0.03; (Chi² = 104.90	, df = 33 (1	1863 P < 0.0000			-0.30 [-0.39 , -0.21]	\rightarrow	Cochran
Test for overall effect: Z = 6. Test for subgroup differences	.68 (P < 0.000	01)					-2 -1 0 1 2 Favours quitters Favours smokers	Library








SUMMARY OF FINDINGS

- Evidence that smoking cessation is associated with improved mental health across 6 different outcomes.
- Strong evidence that mental health does not worsen as a result of quitting smoking.
- Findings robust to multiple sensitivity and subgroup analyses.



QUITTING SMOKING COMPARED TO TAKING ANTIDEPRESSANTS



```
Happiness
```

σ

ncrease


Depression

Anxiety

Stress

Decreased





intEgrating Smoking
Cessation treatment As
part of usual Psychological
care for dEpression and
anxiety (ESCAPE): a pilot
and feasibility trial





PILOT & FEASIBILITY QUESTIONS

Does offering smoking cessation treatment impact on completing usual care?

Do participants engage with the smoking cessation treatment?

Can we conduct a smoking cessation intervention trial in this setting?



IMPROVING ACCESS TO PSYCHOLOGICAL THERAPIES (IAPT)

- Treat common mental illness (mood, OCD, anxiety)
- Receive 1.5 million referrals each year
- Assess 1 million patients each year
- 50% receive therapy
- Evidence based therapies (CBT)








- Pre-registered and published (ISRCTN99531779)
- ESCAPE is a pragmatic randomised and controlled, multicentre, acceptability, feasibility and implementation trial with nested qualitative methods
- Conducted across 4 English regions and included 6 IAPT services



PARTICIPANTS

Inclusion:

- Aged 18+ years
- Depression and/or anxiety (PHQ-9 score of ≥10 and/or GAD-7 score of ≥8)
- Other mental health comorbidities permitted
- Self-reported daily tobacco smokers of ≥1 year Exclusion:
- Had already started IAPT treatment
- Pregnant/breastfeeding
- Considered "too unwell"





INTERVENTION BASIC STRUCTURE





Parallel treatment of smoking and mental health, in IAPT.



Delivered by IAPT therapists during usual therapy sessions during individual sessions.



IAPT service users with depression and/or anxiety, who smoke daily.



5-15 minutes per therapy session, 6+ sessions.



Smoking cessation medication + behavioural support.



TAU + delayed referral to smoking cessation services.



INTEGRATED INTERVENTION CBT







FIG 3 The anxiety cycle in smoking: the trigger is an anxiety-provoking event.




PSYCHOEDUCATIONAL VIDEO





OUTCOMES

- 3- & 6-month follow-up
- IAPT treatment completion
- Quit attempts
- 7-day point prevalence smoking cessation (saliva cotinine or exhaled-CO verified)
- Depression scores (PHQ-9)
- Anxiety scores (GAD-7)
- Treatment satisfaction
- Recruitment rates





Baseline and pre-clinical* characteristics

		Control N=67	Treatment N=68
Age in years		33.7 (11.9)	37.4 (13.3)
Gender, N (%)	Male	27 (40.3%)	22 (32.4%)
	Female	40 (59.7%)	46 (67.6%)
Ethnicity, N (%)	White	60 (89.6%)	61 (89.7%)
	Mixed	4 (6.0%)	3 (4.4%)
	Indian	1 (1.5%)	1 (1.5%)
	Pakistani	2 (3.0%)	1 (1.5%)
	Bangladeshi	0 (0.0%)	1 (1.5%)
	Other	0 (0.0%)	1 (1.5%)
Highest level of education, N (%)	Some high school	1 (1.6%)	1 (1.5%)
	GCSE/O-grade/equivalent	15 (24.6%)	18 (26.9%)
	A-level equivalent	6 (9.8%)	12 (17.9%)
	Apprenticeship	5 (8.2%)	3 (4.5%)
	Other vocational	13 (21.3%)	14 (20.9%)
	Degree	16 (26.2%)	14 (20.9%)
	Higher degree	5 (8.2%)	5 (7.5%)
IMD		18.1 (12.9)	18.3 (12.4)
PHQ-9*		14.9 (5.8)	14.0 (6.1)
GAD-7*		13.7 (4.7)	12.3 (5.1)
Comorbid anxiety, N (%)*	No	34 (50.7%)	41 (61.2%)
	Yes	33 (49.3%)	26 (38.8%)
Comorbid panic attacks, N (%)*	No	58 (86.6%)	59 (88.1%)
	Yes	9 (13.4%)	8 (11.9%)
Comorbid OCD, N (%)*	No	60 (89.6%)	61 (91.0%)
	Yes	7 (10.4%)	6 (9.0%)
Other comorbid mental health condition, N (%)*	No	55 (82.1%)	55 (82.1%)
	Yes	12 (17.9%)	12 (17.9%)
HIS*		2.1 (1.6)	2.6 (1.6)
CPD*		13.1 (7.8)	15.7 (8.4)
Previous number of quit attempts		5.0 (7.0)	3.7 (6.7)


IMD = Index of Multiple Deprivation score, PHQ-9 = Patient Health Questionnaire, GAD-7 = Generalised Anxiety Disorder Questionnaire, OCD = obsessive-compulsive disorder, HSI = Heaviness of Smoking Index, CPD = Cigarettes per day

MAIN ACCEPTABILITY AND FEASIBILITY OUTCOMES AT 3- AND 6-MONTHS FOLLOW-UP

	3-month follow-up, N (%)		6-month follow-up, N (%)	
	Control	Treatment	Control	Treatment
	N=67	N=68	N=67	N=68
Bio-verified self- reported 7-day smoking abstinence	1 (1.5%)	8 (11.8%)	4 (6.0%)	10 (14.7%)
IAPT treatment completion	13 (19.4%)	11 (16.2%)	21 (31.3%)	16 (23.5%)



SURVIVAL CURVE: NUMBER OF DAYS TO TREATMENT COMPLETION, BY TRIAL ARM, N=135



LIMITATIONS

- Trial still in progress data incomplete
- Unable to collect implementation data
- Blinding was unsuccessful in 13-15% of follow-ups
- Predominately recruited white, educated, women in their 30s



SUMMARY OF FINDINGS

- We recruited at an acceptable rate across 4 NHS trusts.
- Attrition was what we expected (33%).
- Practitioners and participants reported that they accepted and were satisfied with the intervention.
- Offering smoking cessation treatment did not impact on engagement with the trial, or with usual IAPT treatment.
- Participants engaged with the smoking cessation treatment.
- Evidence of intervention promise for a future smoking cessation trial.



How does smoking worsen mental health, and how does quitting improve mental health?



Taylor, G. and Truer, J. (2022). An application of the stress-diathesis model: A review about the association between smoking tobacco, smoking cessation, and mental health. International Journal of Clinical and Health Psychology (In press).



Biological pathways – neurotransmitter systems

- Constant fluctuation in withdrawal-induced psychological symptoms is associated with damage in neurotransmitter pathways, which could increase the risk of mental ill-health.
- After breaking the tobacco withdrawal cycle, through smoking cessation, these systems recover in the same way that other systems damaged by smoking reverse after smoking cessation.
- Smoking damages every organ in the body so of course it damages the brain.



Taylor, G. and Truer, J. (2022). An application of the stress-diathesis model: A review about the association between smoking tobacco, smoking cessation, and mental health. International Journal of Clinical and Health Psychology (In press).



Biological pathways - inflammation and oxidative stress

- Oxidative stress and inflammation underly the progression of depression, anxiety and bipolar disorder
- It is well established that smoking has long-term effects on the oxidative stress burden
- Crucially, the association showed a dose-response pattern, such that higher levels of daily smoking led to higher concentrations of oxidative stress biomarkers
- Evidence that those who had stopped smoking for more than 10 years had similar oxidates stress biomarker levels as never smokers



Taylor, G. and Truer, J. (2022). An application of the stress-diathesis model: A review about the association between smoking tobacco, smoking cessation, and mental health. International Journal of Clinical and Health Psychology (In press).



FINAL THOUGHTS

- It's highly likely that smoking damages the brain like it damages other organs in the body.
- There's consistent evidence that stopping smoking is linked to improvements in mental health.
- People who smoke can be reassured that stopping smoking will not worsen and may improve their mood, by reducing anxiety, depression, and stress.
- Clinicians should be reassured that encouraging and supporting smoking cessation in their patients will not worsen and may improve mood.
- There is no reason to fear that people with psychological disorders will have their condition worsened by smoking cessation.



DISSEMINATION


Public Health England

Health Matters

Benefits of stopping smoking for people with poor mental health

For people with a mental health condition, smoking cessation improves both physical and mental health and reduces the risk of premature death.

Stop Stopping smoking smo kina support can be as effective as is effective antidepressants for people with poor reduce the amount mental of psychiatric health medication needed



```
YouTube
```

John Lewis Login servicing-card.johnlewisfinance.com/.../login/


Stopping smoking while dealing with a mental health

▶I 🔌 0:04 / 3:19

condition







Q











GMJM20@BATH.AC.UK





WITH SPECIAL THANKS TO:

CANCER RESEARCH UK PAUL AVEYARD ADDICTION AND MENTAL HEALTH GROUP **KATHERINE SAWYER** PAMELA JACOBSEN NICOLA LINDSON **AMANDA FARLEY** ANDREA LEINBERGER-JABARI **REBECCA TE WATER NAUDE** ANNIKA THEDOULOU NAOMI KING **KATHERINE SAWYER** CHLOE BURKE TOM FREEMAN SALLY ADAMS CHLOE BURKE MARCUS MUNAFÒ CHRIS METCALFE DAVID KESSLER **JAMIE BROWN DOUG HISCOCK** SOPHIA PAPADAKIS **BEN AINSWORTH** KATE BARTLEM **ALISON SHAW** UKCTAS SMOKERS' PANEL / NICOTINE DISCUSSION PANEL PWPS, & RESEARCHERS INVOLVED IN ESCAPE AVON AND WILTSHIRE PARTNERSHIP TRUST NORTHEAST LONDON FOUNDATION TRUST **OXFORD HEALTH NHS FOUNDATION TRUST** BLACK COUNTRY HEALTHCARE PARTNERSHIP TRUST







• Submit questions via the 'Ask a Question' box







Smoking Cessation Leadership Center

CME/CEU Statements

Accreditations:

The University of California, San Francisco (UCSF) School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UCSF designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the webinar activity.

Advance Practice Registered Nurses and Registered Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 CreditTM issued by organizations accredited by the ACCME.

Physician Assistants: The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 CreditTM are acceptable for continuing medical education requirements for recertification.

California Pharmacists: The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for *AMA PRA category 1 Credit*TM. If you are a pharmacist in another state, you should check with your state board for approval of this credit.

California Psychologists: The California Board of Psychology recognizes and accepts for continuing education credit courses that are provided by entities approved by the Accreditation Council for Continuing Medical Education (ACCME). *AMA PRA Category 1 Credit*TM is acceptable to meeting the CE requirements for the California Board of Psychology. Providers in other states should check with their state boards for acceptance of CME credit.

California Behavioral Science Professionals: University of California, San Francisco School of Medicine (UCSF) is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for behavioral health providers. UCSF maintains responsibility for this program/course and its content.

Course meets the qualifications for 1.0 hour of continuing education credit for LMFTs, LCSWs, LPCCs, and/or LEPs as required by the California Board of Behavioral Sciences. Provider # 64239.

Respiratory Therapists: This program has been approved for a maximum of 1.0 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care, 9425 N. MacArthur Blvd. Suite 100 Irving TX 75063, Course **#TBD**.

California Addiction Counselors: The UCSF Office of Continuing Medical Education is accredited by the **California Consortium of Addiction Professional and Programs (CCAPP)** to provide continuing education credit for California Addiction Counselors. UCSF designates this live, virtual activity, for a maximum of 1.0 CCAPP credit. Addiction counselors should claim only the credit commensurate with the extent of their participation in the activity. Provider number: 7-20-322-0722.





<u>Free CME/CEUs</u> will be available for all eligible California providers, who joined this live activity thanks to the support of the California Tobacco Control Program (CTCP)

For our California residents, SCLC offers regional trainings, online education opportunities, and technical assistance for behavioral health agencies, providers, and the clients they serve throughout the state of California.

For technical assistance please contact (877) 509-3786 or <u>Jessica.Safier@ucsf.edu</u>.

Visit CABHWI.ucsf.edu for more information

Webinar Collections with Free CME/CEUs



SCLC is offering <u>FREE CME/CEUs</u> for our recorded webinar collections for a total of **23.5** units.

Visit SCLC's website at: <u>https://smokingcessationleadership.ucsf.edu/free-cmeces-webinar-collections</u>



Free 1-800 QUIT NOW cards





✓ Refer your clients to cessation services



Post Webinar Information

- You will receive the following in our post webinar email:
 - ✓ Webinar recording
 - $\checkmark\,$ PDF of the presentation slides
 - ✓ Instructions on how to claim FREE CME/CEUs
 - ✓ Information on certificates of attendance
 - ✓ Other resources as needed

All of this information will be posted to our website at <u>https://SmokingCessationLeadership.ucsf.edu</u>











SCLC's next live webinar is co-hosted with the National Behavioral Health Network on Tobacco and Cancer Control (NBHN) entitled, "*Journey to a Tobacco-free Certified Community Behavioral Health Clinic (CCBHC): A Conversation*"

- Tuesday, September 20, 2022, 12:30 1:30 pm EDT
- Registration will open soon





Contact us for free technical assistance



- Visit us online at smokingcessationleadership.ucsf.edu
- Call us toll-free at 877-509-3786
- Provide Feedback Copy and paste the post webinar survey link: <u>https://ucsf.co1.qualtrics.com/jfe/form/SV_af6dm7tadtOfg6G</u> into your browser to complete the evaluation!

UCSF Smoking Cessation Leadership Center

National Center of Excellence for Tobacco-Free Recovery





SmokingCessationLeadership.ucsf.edu

Toll-Free 877-509-3786